skip to Main Content

SAFETY & EFFICACY TESTING

Biotherapeutic agents can elicit an adverse immune response when administered in humans. Unintended immune responses can impact both safety and efficacy.  Immunogenicity screening early in the preclinical phase will save time and money by reducing the likelihood of unwanted immune responses cropping up during the development process.

Benefit From Our Extensive Bioassay Capabilities

IBT Bioservices offers a range of services for preclinical evaluation of innate immune system activation, cytokine release and biomarker analysis. We offer fit-for-purpose services from method development all the way through validation and analysis.

Whether you are bringing your assay to us for validation or looking for de novo assay development, our design and development strategy includes:

    • Gathering your assay requirements and objectives
    • Selecting optimal assay format/platform
    • Identifying & coordinating components and optimal time point selection
    • Documentation of procedures, specifications, and results
    • Assay optimization & validation for sensitivity and detection

Immunogenicity Testing Services


Immunogenicity is defined by the  FDA as the propensity of a therapeutic protein to induce an immune response with potential for adverse clinical effect. Whether it is for pharmacokinetics, immunogenicity or biomarker analysis we develop our assays using the best practices and with QC for all assays so they can be adapted for future GLP use and progress toward IND. IBT Bioservices will source or develop the necessary reagents for your assays.

ASSAY DEVELOPMENT
  • Positive control identification
  • Assay format selection
  • Assay design and validation
SERVICES
  • Cell-based neutralization assays
  • ELISAs
  • Cytokine Assays (ICS)
  • Flow Cytometry
  • In vivo PK assessment
  • Dose response assessment
  • Non-clinical bioanalysis

Contact IBT Bioservices
Discuss your bioassay project needs with one of our experts today

Tell us how we can help you:

    Back To Top
    Search
    Fig. 1 Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain). Inoculum 1xLD90=1.0E+05 PFU/mouse
    Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain) 1.0E+05 PFU/mouse
    Survival and weight change in BALB/c mice challenged with INFV A/ Texas/36/91 (H1N1) and treated with antiviral Osletamivir Phosphate (Tamiflu)
    Lung viral load and Survival (30 % weight loss cut-off) in BALB/c mice challenged with INFV H3N2 A/HK/1/68.

    Alpha (UK) – B. 1.1.7 / 501Y.V1

    amino acid mutations: del69–70 HV, del144 Y, N501Y, A570D, D614G, P681H, T761I, S982A, D1118H

    Beta (South Africa) – B.1.351

    amino acid mutations: K417N, E484K, N501Y, D614G, A701V

    Gamma (Brazil) – P.1

    amino acid mutations: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I

    Epsilon (Ca, USA) B.1.427

    amino acid mutations: L452R, D614G

    SARS-CoV-2 Parental Strain Wild Type (Wuhan)
    SARS-CoV-2 D614G Variant

    amino acid mutations: D614G

    Epsilon (Ca, USA) B.1.429

    amino acid mutations: S13I, W152C, L452R, D614G

    SARS-CoV-2 Delta Variant

    amino acid mutations: L452R, E484Q